Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news
Want to stay on top of the science and politics driving biotech today?
Sign up
to get our biotech newsletter in your inbox.
The FDA has sharply cut back on public advisory committee meetings, and this morning STAT’s Lizzy Lawrence explains what she’s hearing from industry leaders, patients, and academic experts on the issue.
Also, Xenon is posting impressive Phase 3 epilepsy results, and generic semaglutide could be produced for just a few dollars a month once patents expire, according to a new analysis.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/03/09/biotech-news-setback-for-roche-breast-cancer-drug/)
